Heartware

Health Canada has granted marketing approval for US-based HeartWare International’s Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.

The system features the HVAD Pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding abdominal surgery generally required to implant competing devices.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Peter Munk Cardiac Centre chief of Cardiovascular Surgery Vivek Rao said: "We gained valuable experience with the HeartWare System under Health Canada’s Special Access program and found it to be an important addition to our treatment options, particularly with difficult-to-treat patients.

"The system features the HVAD Pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding abdominal surgery generally required to implant competing devices."

"With Health Canada approval, we look forward to continuing our positive experience with this device."

In 2012, US Food and Drug Administration (FDA) approved the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.

See Also:

St Paul’s Hospital director of Cardiac Transplant Anson Cheung said: "Approximately the size of a golf ball, the small HVAD Pump allows for ease of implantation and pursuit of less invasive surgical approaches.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Since 2010, we have been able to build an extensive and positive clinical experience with the HVAD Pump. Earlier this year, we commenced LATERAL, a clinical trial to examine the potential benefits of implanting this device through a less invasive left thoracotomy technique, as an alternative to the sternotomy approach associated with many cardiac surgeries."

The system obtained CE Mark approval in the European Union in 2009 and Australian Therapeutic Goods Administration (TGA) approval in 2011.

HeartWare International CEO Doug Godshall said: "We look forward to demonstrating the benefits of the HeartWare System in a larger patient population in Canada, as we gain commercial experience with this device in an important new geography."

Currently, more than 8,000 advanced heart failure patients worldwide have received the HVAD Pump.

Image: The HeartWare Ventricular Assist System featuring the HVAD Pump. Photo: courtesy of PRNewswire / HeartWare International Inc.